Salient features of thiamphenicol: review of clinical pharmacokinetics and toxicity

Sex Transm Dis. 1984 Oct-Dec;11(4 Suppl):336-9.

Abstract

This article reviews specific aspects of the pharmacokinetics and clinical toxicity of thiamphenicol. Studies on the systemic bioavailability in humans of 2.5 g of thiamphenicol given orally showed mean peak levels in plasma of 16.1-18.6 micrograms/ml after about 2 hr, and plasma concentrations of thiamphenicol of greater than 2 micrograms/ml for approximately 17-20 hr. The oral dose of 2.5 g appeared no less bioavailable than the usual 0.5-g parenterally administered dose. The distribution of thiamphenicol to selected urogenital tissues is also summarized. Clinical data on toxicity obtained during 1980-1982 confirmed that thiamphenicol does possess a hematopoietic suppressant potential of the dose-related type, which appeared to be observed only after repeated dosing. On the other hand, thiamphenicol does not appear to be associated with the dose-unrelated, delayed type of hemotoxicity known to occur after therapy with chloramphenicol.

Publication types

  • Comparative Study

MeSH terms

  • Administration, Oral
  • Adult
  • Biological Availability
  • Drug Evaluation
  • Female
  • Hematologic Diseases / chemically induced
  • Humans
  • Kinetics
  • Male
  • Thiamphenicol / administration & dosage
  • Thiamphenicol / adverse effects
  • Thiamphenicol / metabolism*
  • Urogenital System / metabolism

Substances

  • Thiamphenicol